{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T06:16:13Z","timestamp":1675145773171},"posted":{"date-parts":[[2022,11,2]]},"group-title":"In Review","reference-count":43,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Background\n The treatment of relapsed\/refractory multiple myeloma (RRMM) dramatically changed with the emergence of chimeric antigen receptor T (CAR-T) cell therapy. The aim of this study was to evaluate the cost-effectiveness of two CAR-T cell treatments for RRMM patients from the perspective of the Chinese healthcare system.\nMethods\n Markov modelling was used to evaluate Idecabtagene vicleucel(Ide-cel) and Ciltacabtagene autoleucel (Cilta-cel) compared with currently available salvage chemotherapy for patients with RRMM over a lifetime horizon. The model was developed based on data from the three studies: CARTITUDE-1, KarMMa and MAMMOTH. Each CAR-T cell treatments was compared with currently available salvage chemotherapy. The healthcare cost and utility of RRMM patients were collected in a Chinese single institution. Main outcomes were life-years, discounted lifetime costs, discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio.\nResults\n In the base case analysis, 3.5% and 30.4% of RRMM patients were expected to be long-term survivor after 5 years of Ide-cel and Cilta-cel treatment. Compared to salvage chemotherapy, Ide-cel and Cilta-cel were associated with the incremental QALYs of 1.14 and 3.32, and increment cost of US $166,643 and $111,225, leading to ICERs of $146,764 and $33,547 per QALY. In the scenario analyses, the ICER was $138,249 and $28,844 per QALY under assumption that the model starting age is changed from 60 to 55 for Ide-cel and Cilta-cel, and ICER was $148,486 and $40,691 per QALY under assumption that success rate of CAR-T therapy manufacturing was 100%.\nConclusions\n Under the wiling-to-pay of 3 times China's per capita GDP in 2021, Cilta-cel was cost-effectiveness options compared to salvage chemotherapy for patients with RRMM while Ide-cel not. With younger target people, potential price discount and long-term survival improvement, the ICERs of the two CAR-T cell treatments would decrease.<\/jats:p>","DOI":"10.21203\/rs.3.rs-2177083\/v1","type":"posted-content","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T14:45:50Z","timestamp":1667400350000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness Analysis of CAR-T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma in China"],"prefix":"10.21203","author":[{"given":"Weijia","family":"Wu","sequence":"first","affiliation":[{"name":"Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyi","family":"Ding","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhou","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueshan","family":"Sun","sequence":"additional","affiliation":[{"name":"Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengjin","family":"Dong","sequence":"additional","affiliation":[{"name":"Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan AJ","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"key":"ref2","first-page":"373","article-title":"Multiple myeloma: diagnosis and treatment","volume":"95","author":"Michels TC","year":"2017","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95:373\u201383.","journal-title":"Am Fam Physician"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clml.2019.03.025","article-title":"Multiple myeloma: current advances and future directions","volume":"19","author":"Martin T","year":"2019","unstructured":"Martin T, Huff CA. Multiple myeloma: current advances and future directions. Clin Lymphoma Myeloma Leuk. 2019;19(5):255\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi AH","year":"2019","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33:2343\u201357.","journal-title":"Leukemia"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang Y","year":"2020","unstructured":"Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150.","journal-title":"J Hematol Oncol"},{"key":"ref6","first-page":"169","article-title":"Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of Belantamab Mafodotin and selinexor","volume":"13","author":"Joseph NS","year":"2021","unstructured":"Joseph NS, Tai YT, Anderson KC, et al. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of Belantamab Mafodotin and selinexor. Clin Pharmacol. 2021;13:169\u201380.","journal-title":"Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR-T cells","volume":"21","author":"Larson RC","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR-T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay M","year":"2020","unstructured":"MacKay M, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38:233\u201344.","journal-title":"Nat Biotechnol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"C. CAR-T cell immunotherapy for human cancer","volume":"359","author":"June CH","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone M. C. CAR-T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"ref10","unstructured":"Celgene Corporation, a Bristol-Myers Squibb Company. ABECMA\u00ae (idecabtagene vicleucel) prescribing information. https:\/\/packageinserts.bms.co-m\/pi\/pi_abecma.pdf."},{"key":"ref11","unstructured":"Janssen Biotech, Inc and Legend Biotech. CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf."},{"issue":"8","key":"ref12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316. doi:10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up [published online ahead of print, 2022 Jun 4]","volume":"JCO2200842","author":"Martin T","year":"2022","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up [published online ahead of print, 2022 Jun 4]. J Clin Oncol. 2022;JCO2200842. doi:10.1200\/JCO.22.00842.","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi UH","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"24","key":"ref15","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma","volume":"37","author":"Lin JK","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2019;37(24):2105\u201319. doi:10.1200\/JCO.18.02079.","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Relapsed or Refractory Leukemia","volume":"172","author":"Whittington MD","year":"2018","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Relapsed or Refractory Leukemia. JAMA Pediatr. 2018;172(12):1161\u20138. doi:10.1001\/jamapediatrics.2018.2530.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","article-title":"Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada","volume":"6","author":"Furzer J","year":"2020","unstructured":"Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. JAMA Oncol. 2020;6(3):393\u2013401. doi:10.1001\/jamaoncol.2019.5909.","journal-title":"JAMA Oncol"},{"issue":"6","key":"ref18","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s12325-021-01767-x","article-title":"Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland","volume":"38","author":"Moradi-Lakeh M","year":"2021","unstructured":"Moradi-Lakeh M, Yaghoubi M, Seitz P, Javanbakht M, Brock E. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. Adv Ther. 2021;38(6):3427\u201343. doi:10.1007\/s12325-021-01767-x.","journal-title":"Adv Ther"},{"issue":"11","key":"ref19","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13696998.2020.1808981","article-title":"Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective","volume":"23","author":"Cher BP","year":"2020","unstructured":"Cher BP, Gan KY, Aziz MIA, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective. J Med Econ. 2020;23(11):1321\u20139. doi:10.1080\/13696998.2020.1808981.","journal-title":"J Med Econ"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ribera Santasusana JM, de Andr\u00e9s Salda\u00f1a A, Garc\u00eda-Mu\u00f1oz N, Gostkorzewicz J, Mart\u00ednez Llin\u00e0s D, D\u00edaz de Heredia C. Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain. Clinicoecon Outcomes Res. 2020;12:253\u2013264. Published 2020 May 15. doi:10.2147\/CEOR.S241880.","DOI":"10.2147\/CEOR.S241880"},{"issue":"3","key":"ref21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jtct.2020.12.023","article-title":"Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan","volume":"27","author":"Wakase S","year":"2021","unstructured":"Wakase S, Teshima T, Zhang J, et al. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. Transpl Cell Ther. 2021;27(3):241. doi:10.1016\/j.jtct.2020.12.023. e1-241.e11.","journal-title":"Transpl Cell Ther"},{"key":"ref22","author":"Woods B","year":"2017","unstructured":"Woods B, Sideris EB, Palmer S, Latimer NR, Soares MO. (2017). NICE DSU TECHNICAL SUPPORT DOCUMENT 19: PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN HEALTH CARE : A CRITICAL REVIEW REPORT BY THE DECISION SUPPORT UNIT 2 June 2017."},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi UH","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"key":"ref24","author":"Rohatgi A","year":"2017","unstructured":"Rohatgi A. WebPlot, Digitizer, Version 4.0. 2017. https:\/\/automeris.io\/WebPlot-Digitizer."},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot P","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi:10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"ref26","author":"Raje NS","year":"2020","unstructured":"Raje NS, Siegel DS, Jagannath S, et al 3234 Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: Analyses of high-risk subgroups in the KarMMa Study. ASH; December 7, 2020, 2020."},{"key":"ref27","author":"Wang B","year":"2020","unstructured":"Wang B, Liu J, Zhao W-H, et al. 2304 Chimeric Antigen Receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease\u2013a single institution observation in China. ASH; December 6, 2020, 2020."},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder M","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801\u20138. doi:10.1038\/s41375-021-01453-5.","journal-title":"Leukemia"},{"key":"ref29","article-title":"Clinical and basic research on BCMA-CAR T cells in the treatment of multiple myeloma, ChiCTR1800017404","author":"Clinical trial","unstructured":"Clinical trial. Clinical and basic research on BCMA-CAR T cells in the treatment of multiple myeloma, ChiCTR1800017404. http:\/\/www.chictr.org.cn\/showproj.aspx?proj=28864."},{"key":"ref30","unstructured":"Zhejiang Provincial Center for Drug&Medical Device Procurement, https:\/\/www.zjyxcg.cn\/?pageNow=88."},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"e026309","DOI":"10.1136\/bmjopen-2018-026309","article-title":"End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study","volume":"9","author":"Li Z","year":"2019","unstructured":"Li Z, Pan Z, Zhang L, et al. End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study. BMJ Open. 2019;9(3):e026309.","journal-title":"BMJ Open"},{"key":"ref32","author":"Delforge M","year":"2020","unstructured":"Delforge M, Shah N, Rodriguez-Otero P, et al. 3465 Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the BCMA-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the KarMMa Trial. Paper presented at American Society of Hemotology; 2020."},{"issue":"21","key":"ref33","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1002\/cam4.3391","article-title":"Health-related quality of life of patients with multiple myeloma: A real-world study in China","volume":"9","author":"Li X","year":"2020","unstructured":"Li X, Liu J, Chen M, et al. Health-related quality of life of patients with multiple myeloma: A real-world study in China. Cancer Med. 2020;9(21):7896\u2013913. doi:10.1002\/cam4.3391.","journal-title":"Cancer Med"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12955-018-1036-2","article-title":"EQ-5D-5L norms for the urban Chinese population in China","volume":"16","author":"Yang Z","year":"2018","unstructured":"Yang Z, Busschbach J, Liu G, Luo N. EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes. 2018;16(1):210. doi:10.1186\/s12955-018-1036-2. Published 2018 Nov 8.","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"ref35","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.18553\/jmcp.2021.27.9.1315","article-title":"Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma","volume":"27","author":"Beinfeld M","year":"2021","unstructured":"Beinfeld M, Lee S, McQueen B, Fluetsch N, Pearson SD, Ollendorf DA. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. J Manag Care Spec Pharm. 2021;27(9):1315\u201320. doi:10.18553\/jmcp.2021.27.9.1315.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"111","author":"Sarkar RR","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2019;111(7):719\u201326. doi:10.1093-\/jnci\/djy193.","journal-title":"J Natl Cancer Inst"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni L","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"D\u2019Agostino M","year":"2020","unstructured":"D\u2019Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better? Leukemia. 2020;34:21\u201334.","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL [published online ahead of print, 2022 Aug 31]","author":"Zhang J","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL [published online ahead of print, 2022 Aug 31]. Nature. 2022. 10.1038\/s41586-022-05140-y. doi:10.1038\/s41586-022-05140-y.","journal-title":"Nature"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/heapol\/czw096","article-title":"Understanding and improving the one- and three-times GDP per capita cost-effectiveness thresholds","volume":"32","author":"Robinson LA","year":"2017","unstructured":"Robinson LA, et al. Understanding and improving the one- and three-times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141\u20135.","journal-title":"Health Policy Plan"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille E","year":"2015","unstructured":"Marseille E, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118\u201324.","journal-title":"Bull World Health Organ"},{"key":"ref42","volume-title":"cost\u2013effective threshold of a quality\u2013adjusted life year in China","unstructured":"Estimation of the cost\u2013effective threshold of a quality\u2013adjusted life year in China based on the value of statistical life."},{"key":"ref43","volume-title":"Cost\u2013Effectiveness Threshold for Health Technology Assessment in China","unstructured":"Informing a Cost\u2013Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2177083\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2177083\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T06:44:35Z","timestamp":1675061075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2177083\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":43,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2177083\/v1","relation":{},"subject":[],"published":{"date-parts":[[2022,11,2]]},"subtype":"preprint"}}